International Journal of Rheumatology / 2009 / Article / Tab 2

Review Article

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation

Table 2

Clinical and demographic features of our six SS patients treated with rituximab.

Pt.Age*/ sexAge at SS diagnosisAge at NHL diagnosisAnti-SSA/SSB positivitySS criteriaHCVRF positivityCryo-Ig(pos/type)CMLow C4Persistent parotid swellingB symptomsVasculitisBM VDJ restrictionExtraglandular manifestations

150/F3150SSA/SSBI, II, III, IV, V, VINoNoNoNoNoyes, bilateralNoNopolyclonalArthralgias, fatigue, fibromyalgia
259/F5559SSA/SSBI, II, III, IV, V, VINoyesType IIIgM-kyesyes, bilateralNoyesoligoclonalNeuropathy, ILD, arhralgias, fatigue
347/F4147SSA/SSBI, II, III, V, VINoyesType IIIgM-kyesyes, bilateralNoyespolyclonalNeuropathy, arthralgias, fatigue
442/F4142SSA/SSBI, II, III, V, VINoyesType IIIgM-kyesyes, monolateralNoNomonoclonalThyroiditis, arthralgias, fatigue
554/F46n.a.SSA/SSBI, II, III, IV, V, VINoyesNoNoNoyes, bilateralNoNopolyclonalErosive arthritis, fatigue
659/F57n.a.SSAI, II, III, V, VINoyesType IIIgM-kyesyes, bilateralNoyespolyclonalRaynaud, neuropathy, arthritis, fatigue

Legend: SS: Sjögren’s syndrome; HCV: hepatitis C virus; NHL: non-Hodgkin lymphoma; anti-SSA/SSB: anti-ENA antibodies with SSA/SSB specificity; RF: rheumatoid factor; cryo-Ig: serum crioglobulins; MC: monoclonal component; ILD: interstitial lung disease; BM VDJ: bone marrow variable, diversity and joining region rearrangement; n.a.: not applicable.
*age at RTX therapy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.